The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 7 of the 33 sources its claims cite were checked for support.
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age
Open accessAbstract
Objective: To compare body composition and metabolic outcomes at 7–9 years in offspring of women with gestational diabetes (GDM) randomized to metformin (±insulin) or insulin treatment during pregnancy. Research design and methods: Children were assessed at 7 years in Adelaide (n=109/181) and 9 years in Auckland (n=99/396) by anthropometry, bioimpedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI) (n=92/99) and fasting bloods (n=82/99). Results: In the Adelaide subgroup, mothers were similar at enrollment. Women randomized to metformin versus insulin had higher treatment glycemia (p=0.002) and more infants with birth weight >90th percentile (20.7% vs 5.9%; p=0.029). At 7 years, there were no differences in offspring measures. In Auckland, at enrollment, women randomized to metformin had a higher body mass index (BMI) (p=0.08) but gained less weight during treatment (p=0.07). Offspring birth measures were similar. At 9 years, metformin offspring were larger by measures of weight, arm and waist circumferences, waist:height (p<0.05); BMI, triceps skinfold (p=0.05); DXA fat mass and lean mass (p=0.07); MRI abdominal fat volume (p=0.051). Body fat percent was similar between treatment groups by DXA and BIA. Abdominal fat percentages (visceral adipose tissue, subcutaneous adipose tissue and liver) were similar by MRI. Fasting glucose, triglyceride, insulin, insulin resistance, glycosylated hemoglobin (HbA1c), cholesterol, liver transaminases, leptin and adiponectin were similar. Conclusions: Metformin or insulin for GDM was associated with similar offspring total and abdominal body fat percent and metabolic measures at 7–9 years. Metformin-exposed children were larger at 9 years. Metformin may interact with fetal environmental factors to influence offspring outcomes.
Overview
CoChat Summary
TL;DR
In offspring of women with gestational diabetes randomized to metformin (±insulin) versus insulin, total and abdominal body fat percent and metabolic measures were similar at 7–9 years. Metformin-exposed children in the Auckland 9-year subgroup were larger on several anthropometric and fat-mass measures.
Key findings
- In the Adelaide 7-year subgroup, offspring body composition measures did not differ between treatment arms; mothers randomized to metformin had higher treatment glycemia (p=0.002) and more infants with birth weight >90th percentile (20.7% vs 5.9%; p=0.029).
- In the Auckland 9-year subgroup, metformin offspring were larger by weight (37.0±12.6 vs 32.7±7.7 kg; p=0.049), mid-upper arm circumference (23.0±4.3 vs 21.2±2.9 cm; p=0.02), waist circumference (69.1±12.2 vs 64.2±8.4 cm; p=0.04), and waist:height ratio (0.51±0.08 vs 0.47±0.05; p=0.02); BMI and triceps skinfold were borderline (p=0.051 and p=0.05), DXA arm fat was higher (1568±801 vs 1285±534 g; p=0.047), and MRI abdominal fat volume was borderline (p=0.051).
- Body fat percent was similar by DXA and BIA, and abdominal fat percentages (visceral, subcutaneous, liver) were similar by MRI/MRS. Fasting glucose, triglycerides, insulin, insulin resistance, HbA1c, cholesterol, liver transaminases, leptin, and adiponectin were similar; ferritin was higher in metformin offspring (52 (40–70) vs 40 (28–59) µg/L; p=0.009).
Methods
- Longitudinal follow-up of offspring from the MiG randomized trial comparing metformin (±supplemental insulin) with insulin for GDM; Adelaide children assessed at ~7 years (n=109/181; metformin 58, insulin 51) and Auckland children at ~9 years (n=99/396; metformin 45, insulin 54), totaling 208 children (28% of the original cohort).
- Assessments included anthropometry, bioimpedance analysis, DXA, MRI/MRS (Auckland n=92/99; Adelaide 12 later MRIs), and fasting bloods (Auckland n=82/99); assessors and data entry were blinded to maternal treatment allocation.
- Between-group comparisons used Student’s t-test, Mann-Whitney U test, and Fisher’s exact test, with significance at 5%; the study had 80% power with 37 children per arm to detect a 2% difference in body fat percent.
Limitations
- Stated: the overall follow-up rate was low (28% of the original cohort; 60.2% Adelaide, 25.1% Auckland), the followed populations differed from the initial MiG trial, and results may not apply to the total cohort; the sites were not combined; small subgroups limited adjustment for gender, ethnicity, and other factors; many variables were measured, risking a chance finding; pubertal status was by parental questionnaire.
- Stated: Auckland mothers were not as well matched at baseline (higher BMI at enrollment in the metformin group, p=0.08; less weight gain during treatment, p=0.07) and the population was more heterogeneous; Adelaide maternal glucose control differed between treatment groups, unlike the overall cohort.
- Evident from the text: the 9-year findings rely on site-specific analyses with modest MRI/MRS sample sizes, and the larger size in metformin-exposed Auckland children was partly borderline and attenuated after excluding children with early puberty (weight and DXA arm fat no longer different, both p=0.07).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 1 Not valid · 19 Not checked · 88 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In one HFD mouse model, administering metformin or placebo orally to a pregnant dam did not influence birth measures.”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Conclusions
What the sources say
- Disputedcites [15] Salomäki, 2014, Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring, PLoS One sourceExperimental — accuracy not yet measured
Our copy reports the opposite for the principal birth measure: the Results section 'The effect of HFD and metformin treatment on the dams and weight of the fetuses (E18.5)' states that fetuses exposed to metformin were significantly lighter at E18.5 (P<0.01) than those of vehicle-treated HFD dams (Fig. 3), and the Discussion explicitly treats E18.5 weight as 'considered as birth weight'. The only gestational outcomes reported as unchanged are dam body weight gain, food intake and litter size (8–9), plus the absence of toxicity signs — so a blanket statement that oral metformin 'did not influence birth measures' contradicts this paper's finding. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Body fat percent measured by dual-energy X-ray absorptiometry (DXA) and bioimpedance analysis (BIA) was no different between the treatment arms”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Introduction
What the sources say
- Supportedcites [7] source
The RESULTS (p. corresponding to passage [2]) state 'There were no differences in DEXA measures between the two groups by unadjusted and adjusted analysis... Bioimpedance measures also showed no difference between the metformin and insulin group in FFM or percentage fat.' The Abstract RESULTS (passage [3]) likewise report that total fat mass and percentage body fat assessed by bioimpedance (n = 221) and DEXA (n = 114) were not different, in 2-year-old offspring of MiG-trial mothers randomized to metformin or insulin (passage [5]). The CONCLUSIONS (passages [1], [6]) reiterate no difference in percentage body fat. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Others have reported that GDM infants >90th centile are more likely to develop obesity and metabolic syndrome as they grow,24–26 but we did not see this in our population.”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Conclusions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 9 years, metformin offspring were larger by measures of weight, arm and waist circumferences, waist:height (p<0.05)”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Body fat percent was similar by DXA (32.0%±8.5% vs 30.3%±6.6%; p=0.28) and BIA (23.6%±8.1% vs 22.3%±7.9%; p=0.43).”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Nine-year follow-up: Auckland subgroup
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
53 more claims
Create a free account to see all 112 claims and to verify the 26 references still open.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 35
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This difference was not found in the Adelaide cohort.”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [86]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies showed that the use of metformin during pregnancy is associated with higher body weight, more visceral and subcutaneous tissue, and higher blood glucose levels when the offspring is 9 years old [113].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [113]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU) study's analyses of 7-to 9-year-old offspring, the 9-year-old offspring exposed to metformin for the treatment of GDM in the Auckland cohort were heavier and had a higher waist-to-height ratio and waist circumference than those exposed to insulin (86).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [86]
In the citing paper
“Notably, 2 studies reported that metformin-exposed children of mothers with polycystic ovary syndrome or GDM were found to weigh more at 471 and 9 years of age.72”
From Gestational Diabetes Mellitus (2019) · cites this paper as [72]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Single adult in household | 6 (8.9) | 7 (14.3) | 0.58 | 5 (11.1) | 3 (5.6) | 0.46 |”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Seven-year follow-up: Adelaide subgroup
Reported 8.9 · recomputed 10.344828
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Nine-year follow-up: Auckland subgroup
“Overall, ethnicity was not different between the two groups (p=0.17)”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Seven-year follow-up: Adelaide subgroup
“| Ethnicity (self-reported) | | | | 0.17 | | | 0.39 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Nine-year follow-up: Auckland subgroup
“BIA (23.6%±8.1% vs 22.3%±7.9%; p=0.43)”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Seven-year follow-up: Adelaide subgroup
“| Total fat % | 18.8±7.9 | 20.8±5.4 | 0.13 | 23.6±8.1 | 22.3±8.9 | 0.43 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Abdominal fat: % of total fat mass | 0.5±0.1 | 0.4±0.1 | 0.56 | 0.5±0.1 | 0.5±0.5 | 0.37 |”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Seven-year follow-up: Adelaide subgroup
Reported 0.5 · recomputed 5.281385
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Nine-year follow-up: Auckland subgroup
“percentage subcutaneous fat (27.6%±12.6% vs 24.4%±9.7%; p=0.18)”
§ Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age > Results > Seven-year follow-up: Adelaide subgroup
“| Abdominal subcutaneous fat % | 17.5±9.6 | 14.1±8.6 | 0.54 | 27.6±12.3 | 24.4±9.7 | 0.18 |”
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Self-citationBalsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
Molecular mechanism of action of metformin: old or new insights?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Diabetologia · doi:10.1007/s00125-013-2991-0 · Cited by 479
Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379
Self-citationGestational Glucose Tolerance and Risk of Type 2 Diabetes in Young Pima Indian Offspring
Franks, P. W., Looker, H. C., Kobes, S., Touger, L., Tataranni, P. A., Hanson, R. L., & Knowler, W. C. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-0823 · Cited by 253
Glueck, C. J. (2004) · Human Reproduction · doi:10.1093/humrep/deh263 · Cited by 250
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
Influence of Maternal Obesity on the Long-Term Health of Offspring
Godfrey, K. M., Reynolds, R. M., Prescott, S. L., Nyirenda, M., Jaddoe, V. W. V., Eriksson, J. G., & Broekman, B. F. P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30107-3 · Cited by 1,059
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 535
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Metadata
- Authors
- Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M.
- Affiliations
- Auckland City Hospital (NZ)
- Auckland University of Technology (NZ)
- University of Auckland (NZ)
- The University of Adelaide (AU)
- Women's and Children's Hospital (AU)
- Corresponding author
- Rowan, Janet A
- Venue
- BMJ Open Diabetes Research & Care
- Publisher
- BMJ
- Published
- 2018-04
- Volume
- 6
- Issue
- 1
- Pages
- e000456
- ISSN
- 2052-4897 (ISSN-L)
- PMC
- PMC5905785
- OpenAlex
- W2797222872
- Cited by
- 305
- References
- 28
- Citations by year
- 2026: 19 · 2025: 42 · 2024: 30 · 2023: 41 · 2022: 37 · 2021: 37 · 2020: 46 · 2019: 33 · 2018: 18
- FWCI
- 37.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Tuwhera (Auckland University of Technology) (submittedVersion, cc-by-nc)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by-nc)
- Funders
- Auckland Medical Research Foundation
- National Health and Medical Research Council
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- gestational diabetes mellitus, metformin, insulin therapy, offspring, abdominal fat, visceral adipose tissue, insulin resistance, metabolic outcomes, fetal programming, birth weight, childhood obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. https://app.cochat.ai/papers/10.1136/bmjdrc-2017-000456
- The paper
- Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018). Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2017-000456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.